LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
Study Details
Study Description
Brief Summary
Conventional monopolar or bipolar transurethral resection of bladder tumors is the most common method for resection of a bladder mass. En bloc resection has demonstrated success in the literature utilizing different techniques and lasers, including utilizing the Ho:YAG and Tm:YAG lasers. A recent metanalysis revealed several benefits to laser en bloc resection including less complications and lower recurrence rate.22 Subsequently, laser technology has also advanced with the development of a super pulsed TFL which overcomes many limitations of prior traditional lasers. Olympus' SOLTIVE™ TFL, which has demonstrated improved maneuverability and control, has a shallow depth of tissue penetration at 0.15mm leading to precise resection and optimal hemostasis. Despite these beneficial characteristics and qualities along with the promising utility of en bloc resection, the Olympus SOLTIVE™ TFL has not been described in en bloc resection of bladder tumors. The investigator seek to determine if the proposed benefits of this device can be realized both pathologically and clinically in en bloc resection of bladder tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This is a prospective study investigating the use of the SOLTIVE™ Thulium Super pulse laser for the treatment of bladder tumors via en bloc resection in patients who present for treatment at the University of Kansas Health System. The study pretreatment evaluation and follow up schedule are the same as used routinely in daily practice, in accordance with standard of care practices. Routine labs (e.g. complete blood count, basic or complete metabolic panel, urinalysis and urine culture), and imaging will be obtained as per standard care at the provider's discretion based on the patient's history and physical exam.
A prospective data collection of the patients with bladder cancer undergoing en bloc resection will be conducted in this study.
A complete medical, surgical and bladder cancer history will be obtained by the surgical team in the pre-operative setting, per standard of care practices.
Patients will be taken to the operating room per standard of care for resection of one or more bladder tumors. The SOLTIVE™ Super Pulsed Thulium laser will be utilized for resection of the tumors in an en bloc fashion.
Technique for en bloc resection of bladder tumor Tumor marked with a circular coagulation blockage border approximately 1.0 cm away from the edge. All visible vessels around the tumor will be coagulated and lasered before the incision to reduce bleeding. Along this mark, a fan-shaped incision into the bladder wall is made until the muscle layer is visible uplift tumor by the force of the irrigation and use of the laser tip, gradually exposing the tumor base tumor base is disconnected tumor is then removed en bloc. If it is unable to be removed through the resectoscope in one piece due to its size, it may be cut into 2 pieces at the surgeon's discretion.
At the surgeon's discretion, the procedure may be converted to a traditional TURBT utilizing either monopolar or bipolar loop electrocautery. Other intraoperative/postoperative decisions based on surgeon discretion and standard of care treatment:
Each specimen will be collected and sent en bloc to the pathology department. Ameer Hazma, MD, a genitourinary pathologist, will review all specimens to decrease interobserver variation.
Urinary symptoms before and after the procedure will be evaluated. This will be assessed via an electronic questionnaire that will be sent to study participants. Symptoms will be evaluated pre-operatively the morning of surgery as well as on post-operative day #3, 7, and 14.
No validated questionnaire for evaluation of urinary symptoms after bladder tumor resection currently exists. From clinical experience, the symptoms patients most commonly report include frequency, urgency, dysuria, or hematuria. The investigator will therefore modified the existing American Urological Association's Symptom score to address these symptoms on a shorter term basis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors |
Procedure: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To determine the ability to obtain identifiable pathologic characteristics of bladder tumor specimens by use the SOLTIVE™ laser during en bloc resection. [6 months]
To determine the ability to obtain identifiable pathologic characteristics of bladder tumor specimens by use the SOLTIVE™ laser during en bloc resection.
Secondary Outcome Measures
- To evaluate the overall recurrence rate as well as the recurrence rate at the prior resection site after SOLTIVE™ en bloc resection of bladder tumors. [6 months]
To evaluate the overall recurrence rate as well as the recurrence rate at the prior resection site after SOLTIVE™ en bloc resection of bladder tumors.
- To evaluate patient symptoms before and after en bloc tumor resection [6 months]
To evaluate patient symptoms before and after en bloc tumor resection
- • To evaluate short-term complications within 3 months after SOLTIVE™ en bloc resection of bladder tumors. [6 months]
• To evaluate short-term complications within 3 months after SOLTIVE™ en bloc resection of bladder tumors.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must be 18 years of age or older.
-
Patient presenting for resection of papillary bladder tumor visualized on cystoscopy
-
New bladder tumor
-
Recurrent tumors
-
Tumor <3cm
Exclusion Criteria:
-
Patient unwilling to undergo en bloc resection
-
Non papillary lesions/tumors
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Kansas Medical Center | Kansas City | Kansas | United States | 66160 |
Sponsors and Collaborators
- University of Kansas Medical Center
Investigators
- Principal Investigator: Jeff Holzbeierlein, University of Kansas Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LaserEn